AU2013269550A1 - Bicyclic heterocycles capable of modulating T-Cell responses, and methods of using same - Google Patents

Bicyclic heterocycles capable of modulating T-Cell responses, and methods of using same Download PDF

Info

Publication number
AU2013269550A1
AU2013269550A1 AU2013269550A AU2013269550A AU2013269550A1 AU 2013269550 A1 AU2013269550 A1 AU 2013269550A1 AU 2013269550 A AU2013269550 A AU 2013269550A AU 2013269550 A AU2013269550 A AU 2013269550A AU 2013269550 A1 AU2013269550 A1 AU 2013269550A1
Authority
AU
Australia
Prior art keywords
group
alkyl
phenyl
substituents
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013269550A
Other languages
English (en)
Inventor
Daan HOMMES
Gijs VAN DEN BRINK
Auke VERHAAR
Francesca Viti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nogra Pharma Ltd
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd filed Critical Nogra Pharma Ltd
Publication of AU2013269550A1 publication Critical patent/AU2013269550A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2013269550A 2012-06-01 2013-05-31 Bicyclic heterocycles capable of modulating T-Cell responses, and methods of using same Abandoned AU2013269550A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261654398P 2012-06-01 2012-06-01
US61/654,398 2012-06-01
PCT/EP2013/061328 WO2013178815A1 (en) 2012-06-01 2013-05-31 Bicyclic heterocycles capable of modulating t-cell responses, and methods of using same

Publications (1)

Publication Number Publication Date
AU2013269550A1 true AU2013269550A1 (en) 2014-12-18

Family

ID=48538005

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013269550A Abandoned AU2013269550A1 (en) 2012-06-01 2013-05-31 Bicyclic heterocycles capable of modulating T-Cell responses, and methods of using same

Country Status (11)

Country Link
US (2) US20150126553A1 (https=)
EP (1) EP2861563B1 (https=)
JP (1) JP2015521195A (https=)
KR (1) KR20150016377A (https=)
CN (1) CN104619687A (https=)
AU (1) AU2013269550A1 (https=)
BR (1) BR112014030039A2 (https=)
CA (1) CA2874919A1 (https=)
IN (1) IN2014DN10214A (https=)
MX (1) MX2014014657A (https=)
WO (1) WO2013178815A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
WO2010091894A2 (en) 2009-02-16 2010-08-19 Giuliani International Limited Methods of treating hair related conditions
CN109999017A (zh) 2012-02-09 2019-07-12 诺格拉制药有限公司 治疗纤维化的方法
CN104284655B (zh) 2012-04-18 2017-10-27 诺格拉制药有限公司 治疗乳糖不耐受的方法
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
CA3010615C (en) 2016-01-14 2024-02-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
MX2020010155A (es) * 2018-03-27 2021-03-25 Univ Texas Compuestos de ox2r.
EP4495101A3 (en) 2019-02-08 2025-04-30 Nogra Pharma Limited Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof
CR20220565A (es) 2020-05-06 2023-01-13 Merck Sharp & Dohme Llc Inhibidores de il4i1 y métodos de uso

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1069385A1 (ru) * 1982-05-07 1990-11-15 Научно-исследовательский институт фармакологии АМН СССР Бромид 2-амино-3-(1-адамантилкарбонилметил)-1-( @ -пиперидино-этил)-бензимидазоли , обладающий способностью угнетать иммунитет
US7868028B2 (en) * 2002-06-17 2011-01-11 Fred Drasner Guanidine compounds as anesthetics and for treatment of nervous system disorders
CA2601458C (en) * 2005-03-15 2011-04-26 Pfizer Inc. Benzimidazolone derivatives as cb2 receptor ligands
EP1926734A1 (en) * 2005-08-22 2008-06-04 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
WO2007084728A2 (en) * 2006-01-19 2007-07-26 Abbott Laboratories 2-imino-benzimidazoles
US20080206287A1 (en) * 2006-09-18 2008-08-28 Reed John C Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands
HRP20191953T8 (hr) * 2008-03-07 2021-06-25 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. DERIVATI 1-BENZIL-3-HIDROKSIMETILINDAZOLA I NJIHOVA UPORABA U LIJEČENJU BOLESTI KOJE SE BAZIRAJU NA EKSPRESIJI MCP-1, CX3CR1 i P40
EP2262777B8 (en) * 2008-03-07 2016-05-04 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1 and cx3cr1

Also Published As

Publication number Publication date
US20170183313A1 (en) 2017-06-29
KR20150016377A (ko) 2015-02-11
JP2015521195A (ja) 2015-07-27
WO2013178815A1 (en) 2013-12-05
MX2014014657A (es) 2015-08-10
US20150126553A1 (en) 2015-05-07
IN2014DN10214A (https=) 2015-08-07
EP2861563A1 (en) 2015-04-22
BR112014030039A2 (pt) 2017-06-27
EP2861563B1 (en) 2017-07-12
CA2874919A1 (en) 2013-12-05
CN104619687A (zh) 2015-05-13

Similar Documents

Publication Publication Date Title
CA2874938C (en) Heterocycles capable of modulating t-cell responses, and methods of using same
EP2861563B1 (en) Bicyclic heterocycles capable of modulating t-cell responses, and methods of using same
CA3137458A1 (en) Fgfr inhibitors and methods of use thereof
US12037323B2 (en) Uracil derivatives as Mer-AXL inhibitors
US20220362229A1 (en) Dimeric immuno-modulatory compounds against cereblon-based mechanisms
US20160318856A1 (en) Substituted Urea eIF2alpha Kinase Activators
JP5567573B2 (ja) アリールグアニジンｆ１ｆ０−ａｔｐアーゼ阻害剤およびそれと関連する方法
AU2010229142A1 (en) P2X3, receptor antagonists for treatment of pain
CA2939219A1 (en) Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
BR112020019399A2 (pt) Compostos macrocíclicos como inibidores de trk quinases
CA3058260A1 (en) 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
CA2957898A1 (en) Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists
CA3173777A1 (en) Inhibitors and degraders of pip4k protein
CA3190539A1 (en) Modulators of myc family proto-oncogene protein
CN115803085A (zh) 新型细胞代谢调节化合物及用途
CA3207475A1 (en) Quinoxaline derivatives and uses thereof
CA2931097A1 (en) Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mglur5
CN114787143A (zh) Zeste增强子同源物2抑制剂及其用途
HK40081164A (en) Novel cell metabolism modulating compounds and uses thereof
WO2020207570A1 (en) Phenazines as inhibitors of discoidin domain receptors 2 (ddr2)
TW201742857A (zh) 醯胺類衍生物、其製備方法、其藥物組合物及其在醫藥上的用途

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted